title: Prelesional complement activation in experimental atherosclerosis. Terminal C5b-9 complement deposition coincides with cholesterol accumulation in the aortic intima of hypercholesterolemic rabbits.
abstract: Cholesterol accumulation in the tunica intima of large and medium sized arteries is a characteristic of atherosclerotic lesion development. Cholesterol activates the complement system in vitro generating C5b-9 complexes, and C5b-9 antigens have been observed in atherosclerotic lesions. We therefore investigated whether complement activation correlates temporally with accumulation of intimal cholesterol in vivo. Frozen sections of aortic tissue from rabbits fed a 0.3% cholesterol diet for 0, 2, 6, and 10 weeks were stained with antibodies directed against neoantigens of the C5b-9 complex. Lipids were detected with oil red O, filipin, and antibodies against apoprotein B. C5b-9 complexes were observed to colocalize with extracellular lipid in the subendothelial space beginning at 2 weeks on the diet and extending past 10 weeks. Quantitation of aorta extracted C5b-9 complexes by an enzyme-linked immunosorbent assay revealed a progressive increase in aortic C5b-9 content as a function of time on the cholesterol diet. An approximately 30-fold increase in aortic C5b-9 occurred between 0 and 10 weeks on the diet, whereas plasma C5b-9 remained at normal levels throughout this time. Aortic cholesterol and triglyceride levels approximately doubled between 0 and 10 weeks on the diet and plasma cholesterol increased nearly 50-fold. Intimal C5b-9 deposition preceded monocyte infiltration and foam cell development. The data indicates that early cholesterol accumulation in the aortic intima results in complement activation. Since complement activation products are chemotactic for monocytes and promote their adhesion to the endothelium, complement may provide a mechanism by which monocytes are attracted to arterial regions of lipid accumulation.
authors.affiliation: Department of Clinical Chemistry, Gothenburg University, Sweden.
authors.forename: P S
authors.initials: PS
authors.lastname: Seifert
authors.forename: F
authors.initials: F
authors.lastname: Hugo
authors.forename: G K
authors.initials: GK
authors.lastname: Hansson
authors.forename: S
authors.initials: S
authors.lastname: Bhakdi
mesh_terms: D000818:Animals; D001011:Aorta / Q000032:analysis / Q000276:immunology* / Q000473:pathology; D001161:Arteriosclerosis / Q000276:immunology* / Q000473:pathology; D002784:Cholesterol / Q000032:analysis / Q000378:metabolism*; D002791:Cholesterol, Dietary / Q000008:administration & dosage; D003167:Complement Activation; D015938:Complement Membrane Attack Complex; D003165:Complement System Proteins / Q000378:metabolism*; D004797:Enzyme-Linked Immunosorbent Assay; D005455:Fluorescent Antibody Technique; D005629:Frozen Sections; D006937:Hypercholesterolemia / Q000276:immunology* / Q000473:pathology; D008055:Lipids / Q000032:analysis; D008297:Male; D011817:Rabbits; D014280:Triglycerides / Q000032:analysis
chemical_list: D002791:Cholesterol, Dietary; D015938:Complement Membrane Attack Complex; D008055:Lipids; D014280:Triglycerides; D003165:Complement System Proteins; D002784:Cholesterol